Loss-of-function mutations in PPARG cause familial partial lipodystrophy type 3 (FPLD3) and severe metabolic disease in many cases. Missense mutations in PPARG are present in ~1:500 people. Whilst mutations are often binarily classified as 'benign' or 'deleterious', prospective functional classification of all missense PPARG variants suggests that their impact is graded.
Abstract
Loss-of-function mutations in PPARG cause familial partial lipodystrophy type 3 (FPLD3) and severe metabolic disease in many cases. Missense mutations in PPARG are present in ~1:500 people. Whilst mutations are often binarily classified as 'benign' or 'deleterious', prospective functional classification of all missense PPARG variants suggests that their impact is graded.
Furthermore, in testing novel mutations with both prototypic 'endogenous' (e.g. prostaglandin J2 (PGJ2)) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic agonists selectively rescue function of some PPARg mutants. Here, we report FPLD3 patients, harbouring two such PPARg mutations (R308P, A261E). Both PPARg mutants exhibit negligible constitutive or PGJ2-induced transcriptional activity but respond readily to synthetic agonists in vitro, with structural modelling providing a basis for such differential ligand-dependent responsiveness. Concordant with this, dramatic clinical improvement was seen following pioglitazone treatment of the patient with R308P mutant PPARg. A patient with A261E mutant PPARg also responded beneficially to rosiglitazone, though cardiomyopathy precluded prolonged thiazolidinedione use. These observations indicate that detailed structural and functional classification can be used to inform therapeutic decisions in patients with PPARG mutations.
Peroxisome proliferator-activated receptor gamma (PPARg) is a nuclear receptor originally identified in adipocytes (1) . Although widely expressed, cell-based, loss-of-function studies clearly attest to its primary role in regulating adipogenesis and adipocyte function, with rodent knockout studies robustly corroborating these data (2, 3) . Heterozygous, dominant negative, loss-of-function mutations in human PPARG were first described in 1999 (4) with subsequent identification of many more receptor defects (5) (6) (7) (8) (9) . Clinical findings in such cases have refined the phenotype, now known as familial partial lipodystrophy type 3 (FPLD3), characterised by a paucity of limb fat, preserved abdominal fat, insulin resistant diabetes, dyslipidaemia with particularly labile, diet-sensitive, hypertriglyceridaemia, polycystic ovarian syndrome and hypertension.
Like many nuclear receptors PPARg has an amino-terminal activation domain (AF1), a central DNA-binding domain (DBD) and a carboxy-terminal ligand-binding domain (LBD).
PPARg heterodimerises with retinoid X receptor alpha (RXR) and transcriptional activation is triggered by ligand-binding, resulting in the release of a corepressor complex and recruitment of a coactivator complex. Fatty acids and eicosanoids can activate PPARg, with PGJ2 considered prototypic of such putative endogenous PPARg ligands (10) (11) . Indeed, structural studies suggest that the ligand binding pocket of PPARg is 'promiscuous' and can accommodate several different fatty acids (3) . Thiazolidinediones (TZDs), a class of synthetic PPARg agonists, promote adipogenesis and improve insulin sensitivity, underpinning their therapeutic use as insulin sensitizers in patients with T2DM (12) .
The fact that as many as 1:500 people may have missense mutations in PPARG recently prompted Majithia et al (7) to generate and functionally characterise all possible missense PPARG mutations, to expedite clinical interpretation of the growing number of missense variants identified in patients.
This resource should aid prompt functional classification of novel PPARG variants. For individuals with established loss-of-function mutations and disease phenotype, therapeutic possibilities are limited. Current options include strict dietary fat and calorie restriction, metformin, insulin, GLP1 agonists and leptin has been tried in patients with very low leptin levels (13) . Isolated reports of TZD use also exist (9,14-15) but responses were variable (summarised in Supplementary Table 1 ).
In characterising the properties of all possible PPARG missense mutations (7) we were struck by two observations. First, the spectrum of functional scores exhibited by the range of all missense PPARG variants suggested that even mutations associated with a monogenic disease are likely to perturb protein function to a variable degree, predisposing to a similarly variable phenotype, rather than fitting an arbitrary designation as disease-causing or benign. Such gradation of PPARg dysfunction is also likely to translate into differential, graded responses to metabolic stress, and to molecularly-targeted therapeutic interventions. Second, we noted that a few variants, like R308P, manifested a clearly abnormal transcriptional response to prototypic 'natural' ligand (e.g. PGJ2), whereas their function when tested with a synthetic agonist was near normal (7) . These in vitro observations suggested that patients harbouring such receptor mutants might respond to treatment with synthetic PPARg agonists. Here, we report the dramatic clinical response of a patient, harbouring the R308P PPARg variant, following treatment with rosiglitazone. We also describe a further novel A261E PPARg mutation, present in two apparently unrelated families, with similarly discordant responses to PGJ2 versus synthetic PPARg agonists.
Research design and methods
Participants provided informed written consent and investigations were approved by local research ethics committees and conducted in accordance with the Declaration of Helsinki.
Assessing transcriptional activity of PPARg mutants
Characterisation of transcriptional activity of PPARg variants was undertaken as described previously (16) . In brief, 293EBNA cells, cultured in DMEM/10%FCS were transfected with Lipofectamine2000 in 96-well plates and assayed for luciferase and β-galactosidase activity following a 36-hour incubation with or without ligand with results representing the mean +/-SEM of at least three independent experiments in triplicate.
Structural modelling of PPARg mutants
Crystallographic modelling of PPARg mutants was undertaken using PPARg structures (1PRG, 2PRG, 1FM9, 2ZK1, 3DZY, 2XKW) with different ligands, with results illustrated using MacPyMOL (Molecular Graphics System, Schrödinger, LLC).
Further methodological details are available in the supplementary material.
Results
Identification of PPARG mutations. Two different heterozygous missense mutations in the ligand binding pocket of PPARg were identified in patients presenting with typical features of FPLD3; an Arg308Pro (R308P) mutation was detected in a New Zealand woman, and an Ala261Glu (A261E) mutation was identified in two unrelated women from South Africa (see supplementary material for further clinical details and Table 1 for biochemical results). Table   1 ), reflecting a similar discordance between failure to respond to PGJ2 and activation with rosiglitazone. These results suggest that the R308P mutant is transcriptionally resistant to both natural ligands present endogenously within transfected cells and PGJ2, with such loss-of-function likely contributing to the patient's lipodystrophic phenotype.
Structural modelling. In the crystal structure of the PPARg LBD, Ala261 and Arg308 are situated on different sides of the ligand binding pocket (Figure 2A ). Arg308, located close to the amino terminus of helix 3 (Figure 2A Figure 2G ). While PGJ2 does not alter the structural architecture of this region ( Figure   2H ); binding of farglitazar, rosiglitazone and pioglitazone can potentially alter the conformation of the loop between helix 2-3, thereby providing a mechanism that counteracts the destabilising effect of the R308P mutation, preserving transcriptional responsiveness to these synthetic ligands ( Figure   2F Ala261 is located in helix 2a (Figure 2A -C) and the size and charge difference of the A261E mutation will cause displacement of helix 2a and the loop to helix 2b, thereby destabilizing the ligand binding pocket. This was confirmed using circular dichroism (CD) studies showing a lower thermal denaturation temperature compared to the wild type receptor (Supplementary Table 1 ). As PGJ2 docks in this part of the ligand binding cavity, its binding to receptor is expected to be impaired ( Figure 2C ). In contrast, receptor occupancy by rosiglitazone, farglitazar and pioglitazone is not structurally dependent on this region, correlating with preservation of transcriptional activation of the A261E mutant ( Figure 2B, Supplementary figure 1 ).
Responses to thiazolidinedione therapy. The R308P proband had previously been treated with dietary advice and metformin, but her metabolic control remained suboptimal, so pioglitazone 30mg/day was commenced, resulting in dramatic improvements in glycaemic control and dyslipidaemia ( Table 2 ). Her hirsutism, hyperandrogenism and acanthosis nigricans also improved.
These changes were largely sustained over a 3-year period without a substantial change in BMI (23.7 kg/m² to 22.0 kg/m² at 12 months and 23.0 kg/m² at 24 months).
One of the A261E patients was twice treated with rosiglitazone (4 mg twice daily) when her glycaemic and triglyceride control deteriorated significantly. On each occasion, this intervention was accompanied by substantial falls in her HBA1c as well as improvements in fasting triglyceride levels, though these remained labile (Supplementary figure 3 ). However, therapy was discontinued because it exacerbated her severe congestive cardiac failure which ultimately caused her death at age 26 years.
Discussion
The remarkable increase in access to and use of next generation sequencing has accelerated discovery of novel Mendelian disorders and detection of mutations in genes known to cause monogenic disorders like FPLD3, where ~1:500 people harbour missense mutations (7) . Whilst most are 'benign' or mild in their impact others are pathogenic, but likely in a graded rather than binary categorical fashion. As synthetic PPARg ligands are licensed treatments and given the severity of the metabolic complications seen in FPLD3 patients, TZDs are obvious therapeutic options. Theoretically, FPLD3 patients could be (a) resistant to TZDs due to the extreme deleteriousness of the underlying PPARg defect, or (b) responsive to therapy with mutations that are unresponsive to low-affinity, endogenous ligands yet activated by higher-affinity synthetic agonists, or (c) potentially 'hyper-responsive' to specific "designer" ligands that can overcome the molecular defect that is particular to a specific receptor mutation.
Here, we report two FPLD3-associated PPARg mutations (A261E, R308P), whose properties fall into the latter categories (b,c above). Despite its transcriptional efficacy with wild type PPARg, PGJ2, a ligand which is prototypic of the various, endogenous fatty acid and eicosanoid PPARg activators, was unable to fully activate transcription mediated by A261E or R308P mutants ( Figure  1B ), whereas exposure to high affinity, synthetic ligands like rosiglitazone, pioglitazone and farglitazar achieved full transcriptional activity. Crystal structures of PPARg bound to either farglitazar, rosiglitazone, pioglitazone or PGJ2 show differences between these ligands in the nature of their occupancy of the binding cavity ( Supplementary Figure 1) and structural modelling provides a plausible basis for differential mutant PPARg responses to prototypic endogenous versus synthetic ligands. Whilst synthetic agonists do not occupy the region of the pocket where A261 is situated, this residue is in close proximity to the location of PGJ2, and other fatty acid ligands (16) . Modelling of the A261E mutation suggests that the alanine to glutamic acid change is likely to perturb PGJ2 binding directly via steric hindrance, whereas receptor interaction with rosiglitazone, pioglitazone and farglitazar would be preserved; correlating with the observed transcriptional responses ( Figure   1B -C).
The R308P mutation involves a different part of the ligand binding cavity and this residue does not make direct contact with ligands. Structural modelling suggests that the Arginine to Proline change would disrupt local hydrogen bond networks, with deleterious conformational consequences affecting transcriptional function of the receptor. Rosiglitazone, pioglitazone and farglitazar (but not PGJ2), bind in proximity to R308, possibly stabilising receptor structure. In particular, pioglitazone, which we have shown binds effectively to the R308P mutant receptor, makes a hydrogen bond with E287 in helix 2, as does R308, counteracting the effect of the R308P mutation which is predicted to disrupt this interaction ( Figure 2F-I) .
In vitro studies with R308P mutant PPARg mirrored her dramatic and sustained response to pioglitazone therapy. Thus, her case highlights the importance of recognizing and then establishing the genetic basis for severe, early-onset, metabolic disease. Identification of a PPARG mutation enabled early treatment with pioglitazone in preference to other standard glucose-lowering therapies, resulting in substantial clinical improvements in all metabolic abnormalities paralleled by specific redistribution of body fat, away from visceral and with expansion of subcutaneous depots.
Moreover, structural modelling and verification with studies of mutant receptor function in vitro,
provide a plausible explanation for in vivo observations. Specifically, impaired receptor activation by endogenous ligands presumably mediates diminished adipogenesis and the FPLD3 phenotype; the subsequent profound therapeutic response to pioglitazone likely reflects the ability of this synthetic agonist to bypass or overcome the molecular consequences of this mutation. In patients harbouring A261E mutant PPARg, we have documented similar, discordant, transcriptional responses to prototypic endogenous ligand versus synthetic agonists. We have shown that this translates into a beneficial therapeutic response to rosiglitazone in one patient with this receptor defect.
Although our observations are based on prismatic case studies, they appear to be supported by structural analyses of the isolated reports of TZD use in FPLD3 patients (Supplementary table 1) ; such concordance between structural modelling of PPARg mutations, transcriptional responses of mutant PPARg to ligands in vitro, and clinical responses to treatment with synthetic agonists in vivo, highlight the potential for this approach to inform individualised therapeutic choices. LMNA sequencing was wildtype but PPARG sequencing identified a novel heterozygous Ala261Glu (A261E) mutation, which was also present in her sibling but not her mother.
Tables

Proband 3, a South African woman developed T2DM and hypertension in her early
thirties. She also reported hirsutism and oligomenorrhoea. She did conceive subsequently and presented in pregnancy with pancreatitis secondary to severe hypertriglyceridaemia. Her brother, aged 39-years, was also known to have T2DM, severe hypertriglyceridaemia (48.9 mmol/L) and had experienced episodes of pancreatitis. His BMI was 27.5 kg/m 2 and lipodystrophy had not been noted clinically.
On examination, Proband 3, was found to have acanthosis nigricans, hirsutism and partial lipodystrophy.
PPARG sequencing in Proband 3 and her brother also revealed the A261E receptor mutation. Their parents were not available for assessment. This family is not known to be related to that of Proband 2, though both families reside in the same geographical region of South Africa.
Supplementary material
Protein expression and purification. The wild type and mutant PPARγ ligand binding domain (amino-acids 204-477) proteins were cloned into pGEX2T (GE Healthcare) with a TEV site instead of a thrombin site. The proteins were expressed in Rosetta (DE3) (Novagen). Cells were grown at 37 • C in 2xTY until OD 600nm = 0.1, induced with 40 µM Isopropyl-D-1-thiogalactopyranoside (IPTG) followed by overnight growth at 20 • C. The bacterial cells were lysed by sonication in a buffer containing 1x PBS, 1% Triton X-100, 5% glycerol, 1 mM Dithiothreitol (DTT) and Complete EDTAfree protease inhibitor (Roche). The soluble protein was bound to glutathione sepharose (GE healthcare), and washed with a buffer containing 1x PBS, 1% Triton X-100, 5% glycerol, 1 mM DTT. Then the bound protein was washed with TEV cleavage buffer containing 25 mM Tris/Cl pH 7.5, 50 mM NaCl, 5% glycerol and 2 mM DTT. The wild type and mutant proteins were eluted from the resin using TEV protease.
Circular Dichroism (CD).
For the circular dichroism experiments, the concentration of WT and mutant PPARγ proteins was 33 µM in 25 mM Tris/Cl pH 7.5, 50 mM NaCl, 5% glycerol and 2 mM DTT. For the melting curves, circular dichroism was monitored
